At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KDNY Chinook Therapeutics, Inc.
Halted 12-26 13:41:36 EST
40.39
+0.00
0.00%
High40.39
Low40.39
Vol0.00
Open40.39
D1 Closing40.39
Amplitude0.00%
Mkt Cap2.90B
Tradable Cap2.44B
Total Shares71.80M
T/O0.00
T/O Rate0.00%
Tradable Shares60.39M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Baillie Gifford Adjusts Portfolio in Q3 2023, NVIDIA Corp Sees Notable Reduction
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.